PL2100898T3 - Sposób zatężania polipeptydu - Google Patents

Sposób zatężania polipeptydu

Info

Publication number
PL2100898T3
PL2100898T3 PL08166902T PL08166902T PL2100898T3 PL 2100898 T3 PL2100898 T3 PL 2100898T3 PL 08166902 T PL08166902 T PL 08166902T PL 08166902 T PL08166902 T PL 08166902T PL 2100898 T3 PL2100898 T3 PL 2100898T3
Authority
PL
Poland
Prior art keywords
polypeptide
concentration
Prior art date
Application number
PL08166902T
Other languages
English (en)
Inventor
Stefan Nilsson
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of PL2100898T3 publication Critical patent/PL2100898T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01061—Hydroxymethylbilane synthase (2.5.1.61)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01024—Alpha-mannosidase (3.2.1.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01046—Galactosylceramidase (3.2.1.46)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Water Supply & Treatment (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL08166902T 2006-04-04 2007-04-04 Sposób zatężania polipeptydu PL2100898T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200600488 2006-04-04
DKPA200600922 2006-07-05
EP08166902.0A EP2100898B1 (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide
PCT/DK2007/000177 WO2007112757A2 (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide
EP07711305.8A EP2004672B1 (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide

Publications (1)

Publication Number Publication Date
PL2100898T3 true PL2100898T3 (pl) 2019-11-29

Family

ID=38472949

Family Applications (3)

Application Number Title Priority Date Filing Date
PL13167427T PL2628746T3 (pl) 2006-04-04 2007-04-04 Sposób zatężania polipeptydu
PL13167428.5T PL2631242T3 (pl) 2006-04-04 2007-04-04 Sposób zatężania polipeptydu
PL08166902T PL2100898T3 (pl) 2006-04-04 2007-04-04 Sposób zatężania polipeptydu

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL13167427T PL2628746T3 (pl) 2006-04-04 2007-04-04 Sposób zatężania polipeptydu
PL13167428.5T PL2631242T3 (pl) 2006-04-04 2007-04-04 Sposób zatężania polipeptydu

Country Status (20)

Country Link
US (6) US20090246187A1 (pl)
EP (4) EP2100898B1 (pl)
JP (6) JP2009532394A (pl)
KR (3) KR20150103339A (pl)
CN (1) CN105233276A (pl)
AU (2) AU2007234195B2 (pl)
BR (1) BRPI0709737A2 (pl)
CA (3) CA2632528C (pl)
DK (1) DK2628746T3 (pl)
ES (3) ES2928096T3 (pl)
HU (1) HUE042402T2 (pl)
IL (4) IL194267A (pl)
MX (1) MX2008012748A (pl)
NO (3) NO347673B1 (pl)
NZ (7) NZ623123A (pl)
PL (3) PL2628746T3 (pl)
PT (1) PT2628746T (pl)
SI (1) SI2628746T1 (pl)
WO (1) WO2007112757A2 (pl)
ZA (2) ZA200805346B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ576986A (en) 2004-01-30 2010-12-24 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
NO347673B1 (no) * 2006-04-04 2024-02-19 Takeda Pharmaceuticals Co En sammensetning som omfatter konsentrert polypeptide og bruk derav.
CA2790786C (en) * 2010-02-24 2019-09-24 Zymenex A/S Process for production and purification of recombinant lysosomal alpha-mannosidase
JP6045493B2 (ja) * 2010-06-25 2016-12-14 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド アリールスルファターゼａのｃｎｓ送達の方法および組成物
JP6073783B2 (ja) 2010-06-25 2017-02-01 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物
CA2803166C (en) * 2010-06-25 2023-03-07 Shire Human Genetic Therapies, Inc. Cns delivery of therapeutic agents
BR112012033214B1 (pt) 2010-06-25 2020-11-03 Shire Human Genetic Therapies, Inc. uso de uma formulação estável compreendendo uma proteína de iduronato-2-sulfatase (i2s), formulação compreendendo a mesma e recipiente
US10336992B2 (en) 2011-07-08 2019-07-02 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase A
US20140377244A1 (en) 2011-12-23 2014-12-25 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
PL2920198T3 (pl) * 2012-11-13 2020-03-31 Chiesi Farmaceutici S.P.A. Oczyszczanie rekombinowanej ludzkiej beta-galaktozydazy galaktocerebrozydowej (rhgalc)
MX2015007494A (es) * 2012-12-11 2015-12-15 Centogene Ag Metodo para diagnosticar leucodistrofia metacromatica.
WO2014110246A1 (en) 2013-01-09 2014-07-17 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
EA202092926A3 (ru) 2014-03-24 2021-10-29 Биовератив Терапьютикс Инк. Лиофилизированные составы, содержащие фактор ix
CN111065735B (zh) * 2017-08-31 2023-07-07 株式会社绿十字 用于纯化硫酸酯酶蛋白的方法
KR102290596B1 (ko) 2020-09-10 2021-08-19 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 주사용 조성물 및 이의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2041280A1 (en) 1990-05-10 1991-11-11 Yosuke Sawada Arylsulfatase
NO960163D0 (no) 1996-01-15 1996-01-15 Thomas Berg Mutasjonsdeteksjon av bovin
ATE217799T1 (de) 1998-01-27 2002-06-15 Hemebiotech As Behandlung von akuter intermittierender porphyria oder anderen porphyrischen krankheiten
DK2270044T3 (en) * 1998-06-09 2015-01-26 Csl Behring Ag Liquid immunoglobulin G (IgG) product
ID27417A (id) * 1998-06-09 2001-04-05 Statens Seruminstitut Proses untuk memproduksi immunoglobulin untuk pemberian melalui intravena dan produk-produk immunoglobulin lainnya
US6537777B1 (en) 1998-07-27 2003-03-25 Hemebiotech A/S Human porphobilinogen deaminase sequences
AUPQ026799A0 (en) * 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
AU774603B2 (en) 1999-07-27 2004-07-01 Zymenex A/S Production of rhPBGD and new therapeutic methods for treating patients with acute intermittent porphyria (AIP) and other porphyric diseases
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
EP1409695A2 (en) 2000-11-15 2004-04-21 Genzyme Corporation Expression system for recombinant proteins
WO2002099092A2 (en) * 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human lysosomal alpha-mannosidase
WO2002098455A2 (en) * 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human arylsulfatase a
WO2003002731A1 (en) 2001-06-29 2003-01-09 Hemebiotech A/S A PROCESS FOR PURIFICATION OF RECOMBINANT PORPHOBILINOGEN DEAMINASE (rhPBGD)
US7232670B2 (en) * 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
WO2003057179A2 (en) 2002-01-11 2003-07-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US7118675B2 (en) * 2002-02-04 2006-10-10 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
CH694697A5 (de) 2004-01-29 2005-06-15 Koelbl Engineering Und Consult Gummimehl-enthaltende Elastomerlegierungen.
NZ576986A (en) * 2004-01-30 2010-12-24 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
PL1740204T3 (pl) 2004-04-01 2018-08-31 Chiesi Farmaceutici S.P.A. Lecznicze zastosowanie alfa-mannozydazy
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
NO347673B1 (no) * 2006-04-04 2024-02-19 Takeda Pharmaceuticals Co En sammensetning som omfatter konsentrert polypeptide og bruk derav.

Also Published As

Publication number Publication date
AU2008229659A1 (en) 2008-10-23
JP2013236633A (ja) 2013-11-28
NO20211305A1 (no) 2008-10-31
KR20150103339A (ko) 2015-09-09
PT2628746T (pt) 2019-04-23
CA2632528C (en) 2022-07-12
US20180289777A1 (en) 2018-10-11
JP2014058521A (ja) 2014-04-03
MX2008012748A (es) 2009-01-07
US8809055B2 (en) 2014-08-19
IL194267A (en) 2015-10-29
ES2928096T3 (es) 2022-11-15
EP2631242B1 (en) 2022-08-03
CA2882501C (en) 2021-09-07
JP5878152B2 (ja) 2016-03-08
NO20084776L (no) 2008-10-31
CA2632528A1 (en) 2007-10-11
KR20090018894A (ko) 2009-02-24
IL194267A0 (en) 2011-08-01
EP2004672A2 (en) 2008-12-24
NZ582045A (en) 2011-07-29
EP2100898A1 (en) 2009-09-16
PL2628746T3 (pl) 2019-07-31
ZA200805346B (en) 2018-11-28
WO2007112757A3 (en) 2008-02-28
NZ588903A (en) 2012-08-31
NO346368B1 (no) 2022-06-27
SI2628746T1 (sl) 2019-04-30
JP2014051503A (ja) 2014-03-20
IL211905A0 (en) 2011-05-31
PL2631242T3 (pl) 2023-03-20
NZ597548A (en) 2013-08-30
ES2713488T3 (es) 2019-05-22
AU2007234195B2 (en) 2013-02-07
EP2628746A2 (en) 2013-08-21
US20090246187A1 (en) 2009-10-01
AU2007234195A1 (en) 2007-10-11
BRPI0709737A2 (pt) 2011-07-26
HUE042402T2 (hu) 2019-06-28
EP2004672B1 (en) 2015-08-19
US20140314735A1 (en) 2014-10-23
US9713634B2 (en) 2017-07-25
ZA200809540B (en) 2019-09-25
US20170202927A1 (en) 2017-07-20
WO2007112757A2 (en) 2007-10-11
CA2882501A1 (en) 2007-10-11
NZ571610A (en) 2011-07-29
DK2628746T3 (en) 2019-04-01
CA2644642A1 (en) 2007-10-11
EP2631242A2 (en) 2013-08-28
KR101504969B1 (ko) 2015-03-24
IL235982A0 (en) 2015-01-29
JP2016104000A (ja) 2016-06-09
CA2644642C (en) 2016-01-26
IL241654A0 (en) 2015-11-30
JP2009532394A (ja) 2009-09-10
AU2008229659B2 (en) 2013-01-31
EP2100898B1 (en) 2019-06-19
NZ623123A (en) 2015-04-24
KR20140057678A (ko) 2014-05-13
ES2744499T3 (es) 2020-02-25
US20120076767A1 (en) 2012-03-29
NZ568728A (en) 2011-09-30
NO20082510L (no) 2008-10-31
CN105233276A (zh) 2016-01-13
US20160193304A1 (en) 2016-07-07
NZ607595A (en) 2014-10-31
JP5384232B2 (ja) 2014-01-08
NO347673B1 (no) 2024-02-19
IL241654B (en) 2019-02-28
EP2628746B1 (en) 2019-01-09
EP2628746A3 (en) 2014-03-19
JP2009273469A (ja) 2009-11-26
EP2631242A3 (en) 2013-10-02

Similar Documents

Publication Publication Date Title
IL241654A0 (en) A process for concentrating a polypeptide
IL207429A0 (en) A method of purifying a peptide
PL2423315T3 (pl) Sposób osiągania lepszej ekspresji polipeptydu
AP2009004746A0 (en) Process for prepaiIrng diaminophenothiazinium compounds
IL197765A0 (en) Methods for purification of polypeptide conjugates
ZA200900836B (en) Process for the purification of FC-fusion proteins
GB0619941D0 (en) Chemical process
ZA200704159B (en) Method for analysis of pellet-cladding interaction
HUE050656T2 (hu) Folyamat a biogáz elõállítására
IL197979A0 (en) Method for peptide synthesis
EP2088136A4 (en) PROCESS FOR PRODUCING HYDROXYADAMANTANE-AMINE
GB0619942D0 (en) Chemical process
EP2006302A4 (en) PROTEIN COMPLEX AND METHOD FOR THE PRODUCTION THEREOF
EP2045324A4 (en) METHODS FOR PRODUCING THE N36 BINDING PEPTIDE
GB0610387D0 (en) Chemical process
EP1968934A4 (en) METHOD FOR OBTAINING PURE OSELTAMIVIR
HK1120274A (en) A process for concentration of a polypeptide
GB2440637B (en) Method of facilitating analysis of a peptide
GB2471803B (en) Chemical process
IL181944A0 (en) A process for the concentration of hcl
GB0610386D0 (en) Chemical process
GB0618832D0 (en) Chemical process
GB0805124D0 (en) Process for modifying proteins
IL193470A0 (en) Process for preparing of 2-alkyl-3-aryl-prop-2- ene-1-ols
GB0624029D0 (en) Process for capture of carbon